Clinical Trial Update: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes testing nivolumab plus ipilimumab in patients with a broad set of rare tumors and notes the study status as active/not recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acinar Cell Carcinoma
• Adenoid Cystic Carcinoma
• Adrenal Cortical Carcinoma
• Anal Canal Neuroendocrine Carcinoma
• Anal Canal Undifferentiated Carcinoma
• Angiosarcoma
• Basal Cell Carcinoma
• Pheochromocytoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING